Wedbush lowered the firm’s price target on Generation Bio (GBIO) to $5.50 from $7 and keeps a Neutral rating on the shares. Xoma (XOMA) will acquire Generation Bio for $4.2913/share plus a non-transferable CVR, with an expected close in February 2026. The firm expects the transaction to proceed and does not anticipate other bidders. The CVR will include cash at closing in excess of $28.97M, 90%-100% of savings on Generation Bio’s office lease obligations, a share of milestone and royalty payments from Moderna (MRNA), and a share of payments from out-license or sale of the ctLNP delivery platform.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GBIO:
- Generation Bio downgraded to Hold from Buy at Jefferies
- Hold Rating on XOMA’s Acquisition of Generation Bio: Balancing Immediate Cash Offer with Potential Future Returns
- Generation Bio Announces Merger with XOMA Royalty
- Generation Bio trading resumes
- Xoma to acquire Generation Bio for $4.2913 per share